All In Biotech

Drug Trial Radar · NCT05469646

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated

Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 1819479 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)

Last checked: Nov 20, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Aug 3, 2022

Primary completion

Dec 20, 2022

Study completion Dec 27, 2022

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jul 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1819479 in healthy male Japanese subjects receiving single rising doses (SRD) in order to provide the basis for a clinical development of BI 1819479 in Japan.

Conditions

  • Healthy

Interventions

  • BI 1819479Drug

    BI 1819479

  • Matching placeboDrug

    Matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients treated who experience treatment-emergent adverse event assessed as drug-related by the investigatorTime frame: Up to 64 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SOUSEIKAI Sumida Hospital

    Tokyo, Sumida-ku, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.